



# CAPT ACTP

**The Canadian Association for Population Therapeutics/  
Association Canadienne pour la Thérapeutiques des Populations**

**Presents:**

**“Managing risk to improve health  
outcomes: how to move population health  
forward in an era of uncertainty”**

## **PROGRAM**

**October 26<sup>th</sup> – 27<sup>th</sup>, 2020  
Virtual Conference**

**Registration**

**<https://www.capt-actp.ca/conference/>**

## **CAPT-ACTP MISSION & VISION**

The CAPT-ACTP Mission is to advance epidemiologic research of therapeutic and other health interventions in Canada by:

- Bringing together diverse perspectives in a neutral forum
- Facilitating open exchange of ideas and collaboration
- Influencing policy and practice

The CAPT-ACTP Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice that may lead to improved health outcomes.

**[www.capt-actp.ca](http://www.capt-actp.ca)**

## **CAPT-ACTP 2019 Conference Committees**

### **Executive:**

President – Luca Pisterzi  
President Elect – Shazia Hassan  
Past President – Lois Mitchell  
Treasurer – Shazia Hassan

### **Finance Committee:**

Treasurer – Shazia Hassan  
Executive Director – Marjorie Morrison  
Administrator – Peggy Kee

### **Local Organizing Committee:**

Members – Peggy Kee

### **Marketing, Membership & Student Committee:**

Chair: Luca Pisterzi  
Student Rep: Shanna Trenaman  
Members – Marjorie Morrison – Executive Director  
Elena Lungu  
Mary de Vera  
Jon Feairs  
Paul Henricks  
Vidhi Thakkar  
Peggy Kee

### **Partnership Committee:**

Chair –Lois Mitchell  
Members – Graeme Ball  
Shazia Hassan (bridge to SPC)  
Adam Haynes  
Paul Henricks  
Elena Lungu  
Dan Palfrey  
Luca Pisterzi  
Peggy Kee  
Mina Tadrous

### **Scientific Committee:**

Co-Chairs – Shazia Hassan  
Members -- Graeme Ball  
Mary de Vera  
Jon Feairs  
Adam Haynes  
Lois Mitchell  
Dan Palfrey  
Luca Pisterzi (ex-Officio)  
Mina Tadrous  
Vidhi Thakkar

## Message from the President

Welcome to the 2020 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference. COVID-19 has had a huge impact on our lives: altering how we work, interact with one another, and carry on with our daily routines. CAPT-ACTP has also adapted, offering its program virtually this year and most importantly, **free to all attendees**. This allows us to engage a broader audience that shares our mission to advance population-based research of therapeutic interventions.

Our theme this year is “**Managing risk to improve health outcomes: how to move population health forward in an era of uncertainty**”, which is timely, given the challenges faced and the unknowns related to the global pandemic.

I would like to thank our sponsors for their generous contributions that have enabled us to host this event, our presenters who have compiled engaging presentations, and our attendees for joining us. I would also like to thank the CAPT-ACTP Board and the various committees that have worked diligently throughout the year to plan this conference.

A special thank you to CAPT-ACTP’s Scientific Program Committee, who has worked hard to create a meaningful and relevant agenda, our Local Organizing Committee, which has worked behind the scenes to ensure this conference is a success, and the Partnership Committee, who has worked closely with our sponsors to incorporate their vision. Without the work of these three committees, this conference would not be possible.

Undoubtedly, this year’s conference experience will be different but by no means less enriching. In previous years, we would convene Monday evening to mingle with colleagues and review posters, instead this will be now be held virtually, with each poster made available on our website. We have also summarized the content of our Annual General Meeting, which will be sent via email to all members.

Please take the time to complete our post-conference evaluation, your input and ideas are highly valued by the 2020 CAPT-ACTP team.

And, make sure to follow us on Twitter at @CAPT\_ACTP and please tweet your conference observations over the next two days with the hashtag #CAPT\_ACTP2020.

**Luca F. Pisterzi, PhD**  
**CAPT-ACTP President**

## **Conference Overview**

**Shazia Hassan**  
**CAPT-ACTP Scientific Program Committee Chair**

**Monday, October 26, 2020**

**11:00AM – 11:15AM Welcome to Day 1**

Speaker: Luca Pisterzi, CAPT-ACTP President

**11:15AM – 12:00PM Opening:** CADTH/CanREValue updates on the progress of RWE in Canada

Moderator: Mina Tadrous, Women's College Hospital

Speakers: Dr. Kelvin Chan (Sunnybrook Odette Cancer Centre),  
Nicole Mittmann, CADTH

**Session Overview:** Since the establishment of the multidisciplinary RWE Core Action Team at CADTH, the team has been working on sharing initiatives, supporting the development of a pan-Canadian approach to the use of RWE and identifying where RWE can add value to regulatory and reimbursement decision-makers. CADTH will present an update on their activities and provide some insights into what the future might hold.

**12:00PM – 1:30PM Session 1:** Making value-based agreements a reality in Canada through Real-World Evidence

**(Sponsor: AstraZeneca Canada Inc.)**

Moderator: Judith Glennie, J.L. Glennie Consulting Inc.

Speakers: Sylvie Bouchard, INESSS  
Winson Cheung, University of Calgary, Oncology Outcomes (O2)  
Parneet Cheema, William Osler Health System  
Barry Stein, Colorectal Cancer Canada

**Session Overview:** There is much discussion about the potential for RWE generation to address clinical and/or economic uncertainties in Canadian health technology assessment (HTA) recommendations. Despite this, there is no consensus on how to operationalize RWE in reimbursement decision making and no agreed-to method for data collection to leverage RWE as part of value-based agreements (VBA). As payer, academic, clinician, and patient group perspectives will be critical in making real-world evidence, this panel will explore the desire among stakeholders to overcome these barriers in Canada, as has already been accomplished in other countries. Fostering trust among different stakeholders is of paramount importance and can be a realistic goal if all parties commit to transparency and shared goals of delivering innovation and improving patient outcomes.

**1:30PM – 1:40PM Break**

**1:40PM – 3:10PM    Session 2:**    Adoption of Novel therapeutics in the Canadian healthcare system: learnings from CAR T cell therapy  
**(Sponsor: Biogen Canada)**  
Moderator: Farah Jivraj, Biogen Canada  
Speakers: Scott Gavura, Cancer Care Ontario  
              Sophie Rochon, Novartis  
              Brent Fraser, CADTH  
              Ralph Meyer, Hamilton Health Sciences Centre  
              Sabrina Hanna, The Cancer Collaborative

**Session Overview:** The continued advancement of cell and gene therapies promises to transform the treatment of disease and delivery of healthcare for patients, while also fundamentally disrupting and straining Canada's traditional HTA and drug reimbursement processes. This panel will explore recent CADTH process updates related to evaluating cell and gene therapies, as well as Canadian case studies & considerations for how to tackle this exciting challenge in Canadian healthcare going forward.

**3:10PM – 3:15PM    Day 1 Summary**  
Speaker:        Luca Pisterzi, CAPT-ACTP President

**Presentation of the Kris Schindel Award**  
Remarks from recipient

**11:00AM – 11:15AM Welcome to Day 2**

Speaker: Luca Pisterzi, CAPT-ACTP President

**11:15AM – 12:45PM Session 3:** Modern methods of generating Real World Evidence to demonstrate value

**(Sponsor: IQVIA Canada)**

Moderator: Brad Millson, IQVIA Canada

Speakers: Farah Husein, Takeda  
Charles Victor, ICES  
Francois Peloquin, Pfizer  
Laurie Lambert, CADTH

**Session Overview:** This session will showcase how the collection of Real World Evidence (RWE) in Canada is rapidly evolving. We will examine innovative approaches to generating, analyzing and interpreting RWE and how that can be used to support value decisions in the health care system. Panelists will discuss new developments in RWE, views of the importance of RWE and its application to subjects such as value based agreements, healthcare decision making and addressing unmet needs.

**12:45PM – 01:00PM Break**

**01:00PM – 2:00PM Session 4: Oral Presentations**  
**(Sponsors: Gilead Sciences Canada Inc. & J.L. Glennie Consulting)**

**Breakout Room 1: Policy and Reimbursement**

Moderator: Adam Haynes

*Impact of Patented Medicine Prices Review Board new reference countries on drug prices in Canada: A comparison of current and anticipated list prices for top drugs in the country*

Presenter: Chloé Langevin (student)

*A retrospective view on plan sustainability in 2019 from a large Canadian private payer*

Presenter: Anjila Arora

*A review of 20 years of drug delisting: what are the learnings for Canadian policy-makers?*

Presenter: Teagan Maier-Downing

*Reimbursement Recommendations of Conditionally-Approved Cancer Drugs in Canada*

Presenter: Emily Arthur (student)



*Analysis of biosimilars private claims data in Canada*  
Presenter: Dylan Lamb-Palmer

### **Breakout Room 2: Real-world Studies**

Moderator: Jon Feairs

*Using real world data to determine health system costs of Canadians diagnosed with chronic lymphocytic leukemia*  
Presenter: Soo Jin Seung

*Impact of the COVID-19 pandemic on chronic pain management: A web-based pan-Canadian study*  
Presenter: Anais Lacasse

*Sociodemographic, Disease, and Medication Profile of RA Patients under 65 years Compared with 65 Years or Older at Registry Enrollment: Data from A Rheumatoid Arthritis Cohort*  
Presenter: Mohammad Movahedi

*Comparing Academic and Community Practices in the Management of Rheumatoid Arthritis: Data from the OBRI Registry*  
Presenter: Elliot Hepworth (student)

*Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)*  
Presenter: Huah Shin Ng (student)

### **Breakout Room 3: Chronic Diseases & Care**

Moderator: Paul Henricks

*Evaluation of the long-term cost-effectiveness of the Dexcom G6 continuous glucose monitor versus self-monitoring of blood glucose in people with type 1 diabetes in Canada*  
Presenter: Stéphane Roze

*Non-Steroidal Anti-Inflammatory Drug Use Does Not Adhere To Prescribing Guidelines for Older Men or Women with Dementia*  
Presenter: ShannaTrenaman (student)

*Examining self-monitoring of blood glucose in the Nova Scotia public pharmacare program*  
Presenter: Troy Hillier (student)

*Persistence in Rheumatoid Arthritis Patients on Biosimilar and Bio-Originator Etanercept: A Pooled Analysis of Pan-Canadian Cohorts*  
Presenter: Cristiano Moura

*Mental health in the workplace: The economic costs of productivity losses due to presenteeism and sickness absence in Canadian workers having psychological distress*  
Presenter: Mahée Gilbert-Ouimet

**2:00PM – 2:15PM    Break**

**2:15PM – 3:45PM    Session 5:**    Pharmacoeconomic Analysis and Outcome-based agreements: What does it mean for Canadian Private Payers?

**(Sponsor: SunLife)**

Moderator: Julie Blouin, SunLife

Speakers: Lou Garrison, University of Washington

Ned Pojskic, Greenshield

Daria O'Reilly, TELUS Health

Sumeet Singh, Eversana

**Session Overview:** With the growing number of high-cost drugs, many Canadian private payers include cost-effectiveness as part of their value assessment for new drugs or new indications. In Canada's mixed healthcare system, while the economic perspective of a publicly funded health care payer is well established, the perspective of private payers is not. It's common to have real-world evidence and outcome-based agreements discussed from the lens of public payers, but what about private payers? Is the private sector ready for these types of agreements? What can we learn from other countries that have factored in private payers like the U.S.?

In the first part of this panel session, speakers will discuss the value of economic evaluations for Canadian private payers, and which costs, outcomes, time horizon and cost-effectiveness thresholds are relevant for an analysis in adopting a Canadian private payer's perspective. In the second part of the panel, speakers will discuss the gaps and key elements to consider when implementing outcome-based agreements that would involve private payers.

**3:45PM – 4:00PM    Closing Remarks – awards presentations**

Speaker:        Shazia Hassan, CAPT-ACTP President 2021

**Abstract Booklet and Posters** can be found at <https://www.capt-actp.ca/conference/>

For any inquiries, please contact Ms. Peggy Kee ([peggy.kee@sunnybrook.ca](mailto:peggy.kee@sunnybrook.ca)), or visit the CAPT-ACTP website at: ([www.capt-actp.ca](http://www.capt-actp.ca)).

**2020 Conference Partners**

**LEVEL 1**

AstraZeneca Canada Inc.  
Biogen  
IQVIA  
SunLife

**LEVEL 2**

Gilead Sciences Canada Inc.  
J.L. Glennie Consulting Inc.

**LEVEL 3**

Astellas  
Hoffmann-La Roche  
HOPE Research Centre  
IHE Institute of Health Economics  
Leo Pharma  
PDCI  
Takeda

**We gratefully acknowledge sponsorship of the 2020 CAPT-ACTP conference by the following donors:**

LEVEL 1 PARTNERS



LEVEL 2 PARTNERS



J.L. Glennie Consulting Inc.



LEVEL 3 PARTNERS

